Entrada Therapeutics (TRDA) EV to EBIT (2024 - 2025)
Entrada Therapeutics' (TRDA) EV to EBIT stood at 66.98 in Q1 2025, up 289.8% from 17.18 a year earlier and up 474.1% from the prior quarter.
Entrada Therapeutics (TRDA) EV to EBIT (2024 - 2025) Analysis & Trends
On a TTM basis, Entrada Therapeutics' EV to EBIT came in at -21.75 as of Mar 31, 2025; for FY2024, it was 11.67.
- Per Business Quant, the preceding three quarters came in at 11.67 (Q4 2024), 8.99 (Q3 2024) and 3.69 (Q2 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn |
| 10 | Entrada Therapeutics | 205.54 Mn | -172.82 Mn | - |
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 66.98 |
| Dec 31, 2024 | 11.67 |
| Sep 30, 2024 | 8.99 |
| Jun 30, 2024 | 3.69 |
| Mar 31, 2024 | 17.18 |
Entrada Therapeutics EV to EBIT API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ev-to-ebit&ticker=TRDA&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ev-to-ebit", "ticker": "TRDA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=ev-to-ebit&ticker=TRDA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();